Metal-Based Drugs

PDF
Metal-Based Drugs / 1994 / Article

On this page

AbstractCopyright

Open Access

Volume 1 |Article ID 194963 | 5 pages | https://doi.org/10.1155/MBD.1994.305

Synthesis, Characterization and High In Vitro Antitumour Activity of Novel Triphenyltin Carboxylates

Marcel Gielen,1 Abdelaziz El Khloufi,3 Monique Biesemans,1,2 Abdeslam Bouhdid,3 Dick de Vos,4 Bernard Mahieu,5 and Rudolph Willem1,2

1Free University of Brussels (V.U.B.), Pleinlaan 2, Faculty of Applied Sciences, Laboratory for General and Organic Chemistry (AOSC), Room 8G512, Belgium

2Free University of Brussels (V.U.B.), Pleinlaan 2, High Resolution NMR Center, Belgium

3Free University of Brussels (V.U.B.), Pleinlaan 2, Faculty of Sciences, Belgium

4Medical Department, Pharmachemie BV, The Netherlands

5Catholic University of Louvain, INAN, Belgium

Received17 Jan 1994
Accepted14 Feb 1994

Abstract

The synthesis and spectral characterization of six novel triphenyltin compounds are described. The in vitro antitumour activity of three of these compounds against two human tumour cell lines, MCF-7, a mammary tumour, and WiDr, a colon carcinoma, was determined. All three compounds are more active than cis-platin, etoposide and doxorubicin against both tumour cell lines. They are as active as mitomycin C against WiDr, but less active against MCF-7.

Copyright © 1994 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

23 Views | 10 Downloads | 14 Citations
PDF Download Citation Citation
Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.